153559-76-3 Usage
Description
6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-CYCLOPROPYL]-NICOTINIC ACID, also known as LG 100268, is a potent RXR agonist with an off-white solid appearance. It is primarily used in the pharmaceutical industry for the evaluation and treatment of non-insulin-dependent (type II) diabetes mellitus (NIDDM).
Uses
Used in Pharmaceutical Industry:
6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-CYCLOPROPYL]-NICOTINIC ACID is used as a potent RXR agonist for the treatment of non-insulin-dependent (type II) diabetes mellitus (NIDDM). Its agonistic properties on the retinoid X receptor (RXR) play a crucial role in modulating the metabolic pathways and improving insulin sensitivity in patients with type II diabetes.
Additionally, due to its chemical structure and properties, it may have potential applications in other areas of pharmaceutical research, such as the development of new drugs targeting other metabolic disorders or diseases. However, further research and development would be required to explore these possibilities.
Biochem/physiol Actions
LG100268 (LG268) is a potent and selective rexinoid and retinoid-X receptor (RXR) agonist. LG100268 binds to the α, β and γ RXR receptors with an IC50 = 3-4 nM and has no activity at the RAR retinoic acid receptors.
Check Digit Verification of cas no
The CAS Registry Mumber 153559-76-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,3,5,5 and 9 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 153559-76:
(8*1)+(7*5)+(6*3)+(5*5)+(4*5)+(3*9)+(2*7)+(1*6)=153
153 % 10 = 3
So 153559-76-3 is a valid CAS Registry Number.
InChI:InChI=1/C24H29NO2/c1-15-12-18-19(23(4,5)9-8-22(18,2)3)13-17(15)24(10-11-24)20-7-6-16(14-25-20)21(26)27/h6-7,12-14H,8-11H2,1-5H3,(H,26,27)
153559-76-3Relevant articles and documents
Bromomethyl Silicate: A Robust Methylene Transfer Reagent for Radical-Polar Crossover Cyclopropanation of Alkenes
Luo, Wenping,Fang, Yewen,Zhang, Li,Xu, Tianhang,Liu, Yongjun,Li, Yan,Jin, Xiaoping,Bao, Jiakan,Wu, Xiaodong,Zhang, Zongyong
, p. 1778 - 1781 (2020/03/11)
A general protocol for visible-light-induced cyclopropanation of alkenes was developed with bromomethyl silicate as a methylene transfer reagent, offering a robust tool for accessing highly valuable cyclopropanes. In addition to α-aryl or methyl-substituted Michael acceptors and styrene derivatives, the unactivated 1,1-dialkyl ethylenes were also shown to be viable substrates. Apart from realizing the cyclopropanation of terminal alkenes, the methyl transfer reaction has been further demonstrated to be amenable to the internal olefins. The photocatalytic cyclopropanation of 1,3-bis(1-arylethenyl)benzenes was also achieved, giving polycyclopropane derivatives in excellent yields. With late-stage cyclopropanation as the key strategy, the synthetic utility of this transformation was also demonstrated by the total synthesis of LG100268.
THERAPEUTIC COMPOUNDS
-
Page/Page column 24, (2013/03/28)
The invention provides compounds of formulae (I), (II), (III), and (IV): and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease.
ABC EXPRESSION PROMOTERS
-
, (2008/06/13)
The ABCA1 mRNA expression-promoting agent, LXRα mRNA expression-promoting agent, ABCG1 mRNA expression-promoting agent, cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity.
